Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.660
-0.100 (-5.68%)
Jul 29, 2026, 11:31 AM EDT - Market open
Black Diamond Therapeutics Employees
Black Diamond Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 3 or -12.50% compared to the previous year.
Employees
21
Change (1Y)
-3
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$2,057,667
Market Cap
95.12M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 21 | -3 | -12.50% |
| Dec 31, 2024 | 24 | -30 | -55.56% |
| Dec 31, 2023 | 54 | -11 | -16.92% |
| Dec 31, 2022 | 65 | -21 | -24.42% |
| Dec 31, 2021 | 86 | 17 | 24.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Pelthos Therapeutics | 92 |
| Verrica Pharmaceuticals | 76 |
| ImmuCell | 73 |
| Rani Therapeutics Holdings | 71 |
| Biomea Fusion | 40 |
| Oncolytics Biotech | 29 |
| ProMIS Neurosciences | 11 |
BDTX News
- 4 weeks ago - Black Diamond Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Black Diamond Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Transcript: Study result - Transcripts
- 2 months ago - Black Diamond Therapeutics Press release: Study result - Filings
- 2 months ago - Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations - GlobeNewsWire
- 2 months ago - Black Diamond Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC - GlobeNewsWire